Preventive vaccination of pneumococcal disease under the dissemination of COVID-19

Abstract

Under the coronavirus disease 2019 (COVID-19) pandemic, special attention should be paid to minimize the morbidity risk of all infections controlled by specific prophylaxis. During preparation for the epidemic season, the organization and conduct of vaccination against influenza and pneumococcal infection is a particularly crucial task of public health. Priority immunization should be provided to patients from epidemiological and social risk groups. This article presents an overview of the data on pneumococcal infection vaccination efficiency in various population groups as well as on its reasonability for preventing superimposed infection development in COVID-19 infection. In addition to children and decreed groups of the adult population, vaccination against pneumococcal infection is indicated for patients with chronic diseases. This enables us to reduce the risk of complications in case of a new coronavirus infection. Particular attention should be paid to immunizing medical personnel, who are at high risk of infection, play a significant role in controlling the pandemic, and need protection. With the continuous spread of COVID-19, vaccination is necessary in compliance with additional measures to ensure safety (patient routing, disinfection intensification in vaccination rooms, etc.).

Keywords

pneumococcal infection / Streptococcus pneumoniae / risk groups / preventive vaccination

References

[1] Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on preventive vaccination against pneumococcal infections in adults. Russian Pulmonology. 2019;29(1):19-34. (In Russ). doi: 10.18093/0869-0189-2019-29-1-19-34.

[2] Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых // Пульмонология. − 2019. – Т.29. − №1. – С. 19–34. doi: 10.18093/0869-0189-2019-29-1-19-34.

[3] Beloshitskiy GV, Korolyova IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococci isolated from patients with pneumococcal meningitis. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2011;13(3):261-266. (In Russ).

[4] Белошицкий Г.В., Королёва И.С., Миронов К.О. Фенотипическая и генотипическая характеристика штаммов пневмококков, выделенных от больных пневмококковым менингитом // Клиническая микробиология и антимикробная химиотерапия. − 2011. – Т.13. − №3. – С. 261–266.

[5] Briko NI. Epidemiologiya, klinika i profilaktika pnevmokokkovoi infektsii: Uchebnoe posobie dlya vrachei. Nizhnii Novgorod: Remedium Privolzh’e; 2017. (In Russ).

[6] Брико Н.И. Эпидемиология, клиника и профилактика пневмококковой инфекции: Учебное пособие для врачей. Нижний Новгород: Ремедиум Приволжье; 2017.

[7] Tatochenko VK, Ozeretskovskii NA. Immunoprofilaktika-2018: Spravochnik. 13th ed. Moscоw: Borges; 2018. (In Russ).

[8] Таточенко В.К., Озерецковский Н.А. Иммунопрофилактика-2018: Справочник. 13-е изд. − М.: Боргес, 2018.

[9] McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498-1506. doi: 10.1093/cid/ciy312.

[10] McLaughlin J.M., Jiang Q., Isturiz R.E., et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498-1506. doi: 10.1093/cid/ciy312.

[11] Instruction for Prevenar13 LP-000798-041016 [Internet]. (In Russ). Available from: https://medi.ru/instrukciya/prevenar-13_15117/.

[12] Инструкция к применению лекарственного препарата для медицинского применения Превенар-13 ЛП-000798-041016 [интернет]. Доступно по: https://medi.ru/instrukciya/prevenar-13_15117/.

[13] Nurkka A, Ahman H, Korkeila M, et al. Serum and salivary anti-antibodies in infantsand children immunized with heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20(1):25-33. doi: 10.1097/00006454-200101000-00006.

[14] Nurkka A., Ahman H., Korkeila M., et al. Serum and salivary anti-antibodies in infantsand children immunized with heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20(1):25-33. doi: 10.1097/00006454-200101000-00006.

[15] Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318. doi: 10.1093/cid/cit816.

[16] Rubin L.G., Levin M.J., Ljungman P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318. doi: 10.1093/cid/cit816.

[17] Center for Disease Control and Prevention. Pneumococcal Diseases. Pneumococcal Vaccination. Available at: https://www.cdc.gov/pneumococcal/vaccination.html.

[18] Tsaim CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis. 2008;46(11):1664-1172. doi: 10.1086/587897.

[19] Tsaim C.J., Griffin M.R., Nuorti J.P., Grijalva C.G. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis. 2008;46(11):1664-1172. doi: 10.1086/587897.

[20] Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139-1146. doi: 10.1016/S0140-6736(05)71876-6.

[21] Cutts F.T., Zaman S.M., Enwere G., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139-1146. doi: 10.1016/S0140-6736(05)71876-6.

[22] Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:1004. doi: 10.1136/bmj.c1004.

[23] Maruyama T., Taguchi O., Niederman M.S., et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:1004. doi: 10.1136/bmj.c1004.

[24] Reinert R, Taysi B. Effectiveness of the 13-valent pneumococcal conjugate vaccine: emerging data from invasive pneumococcal disease, pneumonia, acute otitis media and nasopharyngeal carriage. Pediatric pharmacology. 2012;9(3):8-11. (In Russ). doi: 10.15690/pf.v9i3.315.

[25] Райнерт Р., Тайши Б. Новые данные по эффективности 13-валентной пневмококковой конъюгированной вакцины в отношении инвазивных пневмококковых инфекций, пневмоний, острого среднего отита и назофарингеального носительства //Педиатрическая фармакология. − 2012. – Т.9. − №3. – С. 8–11. doi: 10.15690/pf.v9i3.315.

[26] Jacobs DM, Yung F, Hart E, et al. Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States. Vaccine. 2017;35(45):6160-6165. doi: 10.1016/j.vaccine.2017.09.050.

[27] Jacobs D.M., Yung F., Hart E., et al. Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States. Vaccine. 2017;35(45):6160-6165. doi: 10.1016/j.vaccine.2017.09.050.

[28] Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the Community − Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017;35(9):1266-1272. doi: 10.1016/j.vaccine.2017.01.032.

[29] Webber C., Patton M., Patterson S., et al. Exploratory efficacy endpoints in the Community − Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017;35(9):1266-1272. doi: 10.1016/j.vaccine.2017.01.032.

[30] Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-9131. doi: 10.1016/j.vaccine.2011.09.112.

[31] Miller E., Andrews N.J., Waight P.A., et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-9131. doi: 10.1016/j.vaccine.2011.09.112.

[32] Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010–2011: International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 2011 Mar 11–15. Poster 179. Iguacu Falls, Brazil; 2012.

[33] Moore M., Link-Gelles R., Farley M., et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010–2011: International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 2011 Mar 11–15. Poster 179. Iguacu Falls, Brazil; 2012.

[34] Chuchalin AG, Onischenko GG, Kolosov VP, et al. Clinical and epidemiological assessment of the effectiveness of vaccination of children against pneumococcal infection in the Amur region. Journal of Microbiology, Epidemiology and Immunobiology. 2016;(3):57-63. (In Russ). doi: 10.36233/0372-9311-2016-3-57-63.

[35] Чучалин А.Г., Онищенко Г.Г., Колосов В.П., и др. Клиникоэпидемиологическая оценка эффективности вакцинации детей против пневмококковой инфекции в Амурской области // Журнал микробиологии, эпидемиологии и иммунобиологии. – 2016. – №3 — С. 57–63. doi: 10.36233/0372-9311-2016-3-57-63.

[36] Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390. doi: 10.1002/14651858.CD001390.pub4.

[37] Walters J.A., Tang J.N., Poole P., Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390. doi: 10.1002/14651858.CD001390.pub4.

[38] Ignatova GL, Antonov VN. Epidemiological characteristics of chronic respiratory diseases in patients vaccinated against pneumococcal infection. Pulmonologiia. 2017;27(3):376-383. (In Russ). doi: 10.18093/0869-0189-2017-27-3-376-383.

[39] Игнатова Г.Л., Антонов В.Н. Эпидемиологические особенности хронической респираторной патологии при вакцинации против пневмококковой инфекции // Пульмонология. – 2017. – Т.27. – №3. – С. 376–383. doi: 10.18093/0869-0189-2017-27-3-376-383.

[40] Briko NI, Korshunov VA, Vasilyeva IA, Vorobieva AD. Vaccination against pneumococcal infection in adults from risk groups. Tuberculosis and Lung Diseases. 2020;98(5):15-23. (In Russ). doi: 10.21292/2075-1230-2020-98-5-15-23.

[41] Брико Н.И., Коршунов В.А., Васильева И.А., Воробьева А.Д. Вакцинация против пневмококковой инфекции взрослых групп риска // Туберкулез и болезни легких. – 2020. – Т.98. – №5. – С. 15–23. doi: 10.21292/2075-1230-2020-98-5-15-23.

RIGHTS & PERMISSIONS

Eco-vector